NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock Price, News & Analysis $12.69 -0.98 (-7.17%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$12.68 -0.01 (-0.11%) As of 05/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Intellia Therapeutics Stock (NASDAQ:NTLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Intellia Therapeutics alerts:Sign Up Key Stats Today's Range$12.11▼$13.8850-Day Range$11.65▼$16.5752-Week Range$6.83▼$28.25Volume9.63 million shsAverage Volume9.17 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$20.25Consensus RatingHold Company Overview Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders. Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach. The company maintains a collaboration and license agreement with Regeneron Pharmaceuticals to advance in vivo therapies for ophthalmic and other systemic diseases. In the ex vivo space, Intellia has entered into an alliance with Novartis to harness CRISPR/Cas9 for engineering allogeneic CAR-T cells for cancer immunotherapy, with the goal of producing “off‐the‐shelf” cell therapies. Founded in 2014 as a spin-out from Caribou Biosciences, Intellia went public in 2016 and is headquartered in Cambridge, Massachusetts, with research operations in the San Francisco Bay Area and an innovation center in the United Kingdom. The company’s leadership team is led by President and Chief Executive Officer John Leonard, M.D., who brings extensive experience in oncology and cell therapy development, supported by a seasoned executive cadre in R&D, manufacturing and regulatory affairs. Intellia serves a global patient population through its proprietary platform and collaborative network, with a focus on creating one‐time treatments that have the potential to transform the standard of care for patients with debilitating genetic diseases. The company continues to advance multiple programs through clinical and preclinical milestones toward regulatory filings and broader commercialization.AI Generated. May Contain Errors. Read More Intellia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreNTLA MarketRank™: Intellia Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 452nd out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingIntellia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 1 strong buy rating, 9 buy ratings, 10 hold ratings, and 3 sell ratings.Upside PotentialIntellia Therapeutics has a consensus price target of $20.25, representing about 59.6% upside from its current price of $12.69.Amount of Analyst CoverageIntellia Therapeutics has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intellia Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intellia Therapeutics are expected to grow in the coming year, from ($3.35) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Intellia Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted37.29% of the float of Intellia Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 4.31.Change versus previous monthShort interest in Intellia Therapeutics has recently increased by 12.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.37 News SentimentIntellia Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Intellia Therapeutics this week, compared to 7 articles on an average week.Search Interest41 people have searched for NTLA on MarketBeat in the last 30 days. This is an increase of 486% compared to the previous 30 days.MarketBeat Follows22 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 2,100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.10% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intellia Therapeutics' insider trading history. Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NTLA Stock News HeadlinesIntellia Therapeutics (NASDAQ:NTLA) Trading 7.3% Higher - Here's What HappenedMay 17 at 3:59 AM | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Lowered to Sell Rating by Wall Street ZenMay 16 at 1:55 AM | americanbankingnews.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500. | Brownstone Research (Ad)Intellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearMay 14, 2026 | finance.yahoo.comWells Fargo Remains a Hold on Intellia Therapeutics (NTLA)May 14, 2026 | theglobeandmail.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $25.00 by Analysts at HC WainwrightMay 14, 2026 | americanbankingnews.comWedbush Remains a Hold on Intellia Therapeutics (NTLA)May 13, 2026 | theglobeandmail.com3 Biotech Stocks That Could Benefit from the Patent Cliff (NTLA)Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets...April 27, 2026 | marketbeat.comSee More Headlines NTLA Stock Analysis - Frequently Asked Questions How have NTLA shares performed this year? Intellia Therapeutics' stock was trading at $8.99 on January 1st, 2026. Since then, NTLA shares have increased by 41.2% and is now trading at $12.69. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) posted its quarterly earnings results on Monday, May, 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.11. The business had revenue of $15.05 million for the quarter, compared to analysts' expectations of $13.81 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 57.47% and a negative net margin of 597.04%. When did Intellia Therapeutics IPO? Intellia Therapeutics (NTLA) raised $102 million in an IPO on Friday, May 6th 2016. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Intellia Therapeutics' major shareholders? Top institutional investors of Intellia Therapeutics include Dimensional Fund Advisors LP (1.92%), Sumitomo Mitsui Trust Group Inc. (1.67%), Amova Asset Management Americas Inc. (1.64%) and Arrowstreet Capital Limited Partnership (1.00%). Insiders that own company stock include John M Leonard, William J Chase, Edward J Dulac III, James Basta, Birgit C Schultes, Eliana Clark, Michael P Dube, David Lebwohl, Laura Sepp-Lorenzino, Glenn Goddard and Jesse Goodman. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW), Meta Platforms (META) and Edwards Lifesciences (EW). Company Calendar Last Earnings5/11/2026Today5/18/2026RBC Capital Markets Global Healthcare Conference 20265/20/2026Jefferies Global Healthcare Conference 20266/03/2026AGM 20266/09/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 NTLA's financial health is in the Green zone, according to TradeSmith. NTLA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NTLA CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees600Year Founded2014Price Target and Rating Average Price Target for Intellia Therapeutics$20.25 High Price Target$49.00 Low Price Target$5.00 Potential Upside/Downside+59.6%Consensus RatingHold Rating Score (0-4)2.35 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$412.69 million Net Margins-597.04% Pretax Margin-597.04% Return on Equity-57.47% Return on Assets-46.24% Debt Debt-to-Equity RatioN/A Current Ratio6.10 Quick Ratio6.10 Sales & Book Value Annual Sales$67.67 million Price / Sales26.20 Cash FlowN/A Price / Cash FlowN/A Book Value$5.80 per share Price / Book2.19Miscellaneous Outstanding Shares139,720,000Free Float135,391,000Market Cap$1.77 billion OptionableOptionable Beta1.93 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:NTLA) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
